CORT ALERT: Class Action Sparks Investor Concerns!

Overview and Recent Developments

Corcept Therapeutics (NASDAQ: CORT) – a biotech focused on cortisol-modulating drugs – is under scrutiny after a major regulatory setback triggered a sharp stock drop and shareholder lawsuits. On December 31, 2025, the FDA issued a Complete Response Letter (CRL) rejecting Corcept’s New Drug Application (NDA) for relacorilant (a cortisol blocker) as a treatment for hypercortisolism (Cushing’s syndrome) (www.drugs.com). The FDA acknowledged the pivotal trials met their primary endpoint but concluded additional evidence of effectiveness was needed before approval (www.drugs.com). Following this news, CORT’s share price plummeted ~50% (from $70.20 on Dec 30 to $34.80) (intellectia.ai), wiping out significant market value. Investors allege that prior to the CRL, management overstated relacorilant’s approval prospects despite FDA feedback. In February 2026, a securities class action (Allegheny County Employees’ Retirement System v. Corcept) was filed, claiming Corcept made false or misleading statements and omissions about relacorilant’s trial data and NDA approval odds (www.sec.gov) (www.globenewswire.com). The class period runs October 31, 2024 through December 30, 2025 – essentially covering the span when Corcept was touting relacorilant’s “powerful” clinical evidence while the FDA had privately warned of inadequate data (intellectia.ai). Corcept “will vigorously defend” against these allegations (www.sec.gov), but the litigation underscores heightened investor concern about management credibility and the company’s pipeline risk.

Dividend Policy & Shareholder Returns

Corcept does not pay a dividend and has never declared or distributed any cash dividends on its common stock (www.sec.gov). This stance is typical for growth-oriented biopharma companies, as cash is reinvested into R&D and commercialization rather than shareholder payouts. Management has explicitly stated it “has never paid dividends” and does not anticipate doing so in the foreseeable future (www.sec.gov). Instead, Corcept has returned capital to shareholders via stock buybacks. The board authorized a $200 million share repurchase program in early 2024 (www.sec.gov), under which the company aggressively bought back stock. In 2025 alone Corcept repurchased about 2.6 million shares in open-market transactions, deploying roughly $173 million of cash (www.sec.gov) (www.sec.gov). (In 2023, a tender offer was used to retire ~$145 million of shares (www.sec.gov).) These buybacks reduced the share count modestly and demonstrate confidence by management, though the timing is notable – a large portion of repurchases occurred ahead of the FDA setback. With the stock now trading far below its 2025 highs, continued repurchases could be an opportunistic use of capital, but investors may question if that cash would be better reserved for pipeline development or shoring up the balance sheet in light of emerging challenges.

Leverage, Balance Sheet & Debt Maturities

Corcept’s balance sheet remains conservatively financed, with no long-term debt and substantial liquidity. As of year-end 2025, the company held $532.4 million in cash and marketable investments (www.sec.gov). Current liabilities were modest at $166 million (mainly payables and accruals) and the only non-current obligations were operating lease liabilities (~$5 million) and some tax and rebate accruals (www.sec.gov). In other words, Corcept carries no bank debt or bonds outstanding, eliminating refinancing or maturity risks. The company has funded its growth internally via operating cash flow and equity, avoiding leverage. In fact, Corcept’s cash pile far exceeds its liabilities, positioning it to weather near-term adversity or invest in R&D/strategic opportunities. With no interest-bearing debt, traditional credit metrics and interest coverage ratios are a non-issue – Corcept’s interest income actually added $21.7 million in 2025 (www.sec.gov) thanks to its invested cash. This debt-free profile gives Corcept financial flexibility and a buffer as it navigates the fallout from the FDA’s denial. No imminent maturities or creditor obligations constrain the company; thus, the focus shifts to how management deploys this liquidity (e.g. further buybacks, funding additional trials, or potential acquisitions) to rebuild shareholder value.

Financial Performance and Valuation

Despite recent turmoil, Corcept’s core business has been profitable and growing. The company’s sole commercial product, Korlym® (mifepristone for hypercortisolism), drove 2025 revenue of $761.4 million, up ~13% from $675.0 million in 2024 (www.sec.gov). Remarkably, sales had surged ~40% in 2024 (from $482.4 million in 2023) (www.sec.gov), reflecting expanded use of Korlym and its authorized generic. Higher volume (a 37% increase in 2025) was the primary revenue growth driver (www.sec.gov), although supply constraints at a specialty pharmacy vendor slightly limited 2025 sales upside (www.sec.gov). Korlym’s gross margin is high (cost of sales was only ~$13 million in 2025) (www.sec.gov), but operating expenses have ballooned – notably R&D ($255M) and SG&A ($449M) in 2025 climbed significantly as Corcept invested in its pipeline and commercial efforts (www.sec.gov). Operating income consequently fell to $44.8 million in 2025 from $137 million in 2024 (www.sec.gov). However, a one-time tax benefit buoyed net income to $99.7 million for 2025 (about $0.95 basic EPS) (www.sec.gov) (www.sec.gov), versus $141.2M ($1.35 EPS) in 2024.

At a recent price in the mid-$30s per share – near the low end of CORT’s 52-week trading range of $32.99 to $117.33 (www.sec.gov) – the stock’s valuation reflects both its profitable current franchise and uncertainty about future growth. Trailing earnings yield a price-to-earnings ratio on the order of 35–40× (using ~$0.82 diluted EPS for 2025 (www.sec.gov)), which is elevated relative to the broader market. On a sales basis, CORT trades around 4.5–5× 2025 revenue, a premium that had been supported by rapid growth and pipeline optimism. Now, with Korlym facing competition (and potential decline) and relacorilant delayed, this multiple appears rich unless Corcept can reignite growth. It’s worth noting many biotech/pharma peers with a single flagship product often trade at high P/E multiples – reflecting expectations of pipeline success or acquisition premium – but those expectations may need recalibration here. Enterprise value is roughly $3.2 billion (after net cash), which is about 4.2× EV/revenue or a steep ~30× EV/EBITDA (using 2025’s reduced operating profit). In short, Corcept’s valuation remains elevated for a company now grappling with a busted NDA and an imminent patent cliff. This suggests that investors are either looking beyond the current setback (betting on other pipeline assets like the oncology use of relacorilant) or that there is still room for downward adjustment if growth stalls. Any re-rating will depend on how the company addresses its risks and executes going forward.

Key Risks and Red Flags

Corcept’s risk profile has intensified, and investors should be aware of several red flags:

– Reliance on a Single Product & Generic Erosion: Corcept is highly dependent on Korlym (mifepristone) for essentially all its revenue. This franchise is now under siege by generics and new competitors. Teva Pharmaceuticals launched a generic version of Korlym in January 2024 after prevailing in a patent challenge (a court ruled Teva’s version did not infringe Corcept’s patents) (www.sec.gov). Corcept appealed but lost – in February 2026, the Federal Circuit affirmed the non-infringement ruling (www.sec.gov) (www.sec.gov). Anticipating this, Corcept introduced its own authorized generic of Korlym in mid-2024 (www.sec.gov) to retain some market share at a lower price point. The company also struck settlements with generic manufacturers Sun Pharma and Hikma, allowing those firms to begin selling generic Korlym in the future (at agreed-upon dates) (www.sec.gov). In effect, multiple generic versions are either on the market or scheduled, which threatens Korlym’s sales volume and pricing power. Corcept acknowledges that generic competition could materially cut revenue and profits (www.sec.gov) (www.sec.gov). Already, to compete on price, Corcept’s net product margins are pressured by rebates and discounts (e.g. $87.9M in 2025 Medicare rebates) (www.sec.gov). The bottom line is that Korlym’s golden days may be numbered; the drug’s contribution could decline sharply over the next 1–2 years as payers and physicians shift to cheaper generics.

– New Alternative Therapies: Compounding the generic threat, alternative Cushing’s therapies have entered the market. Recordati S.p.A.’s Isturisa (osilodrostat), a cortisol synthesis inhibitor, was approved by the FDA in 2020 (initially for Cushing’s disease) and in April 2025 its label expanded to treat all forms of endogenous hypercortisolism (www.sec.gov). Likewise, Xeris Biopharma’s Recorlev (levoketoconazole) gained FDA approval in 2021 for adult Cushing’s patients (www.sec.gov). These drugs, along with older off-label treatments (e.g. ketoconazole), provide physicians with alternatives to Korlym. Corcept warns that if doctors prefer these newer agents or generics, its revenue could drop substantially (www.sec.gov) (www.sec.gov). Indeed, Korlym’s clinical niche (blocking cortisol receptors) competes against therapies that reduce cortisol production; some endocrinologists may opt for the latter, especially if Korlym’s cost or access becomes an issue. The presence of multiple competing products is a red flag for Corcept’s growth trajectory: even before the FDA’s CRL, analysts were watchful of how long Corcept could fend off competition in this narrow orphan disease market.

– Regulatory Setback & Pipeline Risk: The FDA’s refusal to approve relacorilant in Cushing’s (hypercortisolism) is a major blow. Management was “surprised and disappointed” by the CRL (www.drugs.com), as the Phase 3 GRACE trial had met its primary endpoint. However, the FDA could not conclude the benefit-risk was favorable without additional efficacy evidence (www.drugs.com). This suggests the agency saw ambiguities or insufficient duration/robustness in the data – a potential sign that another clinical trial or more data may be required. Such an outcome means relacorilant’s approval (and any associated revenue) will be delayed by possibly several years, if it can be achieved at all. The class action complaint alleges Corcept failed to disclose FDA’s feedback during the NDA review, which included warnings of “inadequate clinical data” and significant review issues (intellectia.ai). Whether or not those claims hold up in court, the situation raises concern about management’s transparency and judgment. Investors must now assess the pipeline with greater skepticism: relacorilant was Corcept’s most advanced candidate (intended as a follow-on to Korlym), and its regulatory fate is uncertain. Other pipeline programs (e.g. relacorilant in oncology, plus earlier-stage candidates like dazucorilant for ALS or miricorilant for liver/metabolic disorders) carry typical biotech development risks. Notably, Corcept is still pursuing relacorilant for platinum-resistant ovarian cancer – the FDA has accepted an NDA in that indication with a PDUFA decision date of July 11, 2026 (www.drugs.com). Positive Phase 3 data (the ROSELLA trial) were reported in early 2026, showing a 35% reduction in risk of death when relacorilant was added to chemotherapy (www.sec.gov). While encouraging, there is no guarantee of approval or commercial success in oncology, which is a new therapeutic area for Corcept. In short, the company’s growth hopes rest on pipeline execution in the face of this recent setback – a risky proposition that may warrant a higher discount rate on the stock.

– Legal and Governance Overhang: The shareholder class action now hanging over Corcept is itself a risk factor. These lawsuits can take years to resolve and may result in reputational damage or financial cost (settlements or judgments). The allegations of misleading investors – specifically, overstating relacorilant’s clinical evidence and approval likelihood (www.globenewswire.com) – cast a shadow on management’s credibility. Even if Corcept ultimately prevails legally, the case could distract leadership and invite closer scrutiny of the company’s communications and controls. This isn’t Corcept’s first brush with shareholder litigation: a prior securities class action in 2019 (related to off-label marketing and revenue concentration issues) was eventually settled for $12 million in 2021. Investors will be watching for any pattern of problematic behavior. Separately, Corcept is also embroiled in an antitrust lawsuit filed by Teva in 2024, which accuses Corcept and its former specialty pharmacy partner of engaging in anti-competitive practices to delay generic Korlym’s uptake (www.sec.gov). Parts of Teva’s complaint have been dismissed, but some claims were reasserted and the case is ongoing (www.sec.gov). If Teva were to prevail, Corcept could face damages or be forced to alter its distribution arrangements. All told, these legal battles highlight governance red flags and could sap resources. Moreover, insider ownership of Corcept is relatively high (~21% held by officers/directors as of early 2026) (www.sec.gov) (www.sec.gov), which can be double-edged – while insiders are clearly invested alongside shareholders, this concentration might also entrench management and make external accountability or takeover attempts more difficult.

– Other Risks: Additional factors to consider include potential regulatory and policy changes. For example, mifepristone (Korlym’s active ingredient) is more famously known as an abortion pill, and any political or legal efforts to restrict mifepristone usage could indirectly impact Corcept’s product (even though Korlym is indicated for Cushing’s syndrome) (www.sec.gov). Drug pricing reforms are another consideration – the Inflation Reduction Act allows Medicare to negotiate prices of certain drugs, though orphan drugs like Korlym (approved only for a rare disease) are currently exempt (www.sec.gov) (www.sec.gov). If Korlym or future Corcept drugs ever lose orphan exclusivity or expand to larger indications, they could become subject to pricing pressures. Manufacturing or supply-chain issues are also a risk: Corcept relies on specialty pharmacies (recently transitioning to a new vendor in 2025) for distribution, and any disruption there can delay getting medication to patients (www.sec.gov) (www.sec.gov). In fact, Corcept noted a new specialty pharmacy, Curant Health, took over in late 2025 after the prior vendor’s performance issues (www.sec.gov) – such changes carry operational risk. Lastly, the company’s heavy R&D spending means it must correctly allocate capital to projects with the highest chance of return; any failure in clinical trials (common in biotech) could result in sunk costs with no payoff.

In summary, Corcept faces a convergence of serious risks: an aging flagship drug facing competitive decline, a delayed replacement therapy, and legal challenges. The recent class action and CRL incident highlight both the internal risk of execution missteps and the external risks of competition and regulation. Investors should factor in these red flags when evaluating the stock’s risk-reward profile.

Open Questions & Outlook

Looking ahead, several open questions will determine whether Corcept can regain investor confidence or if further pain is in store:

– Can relacorilant be salvaged in Cushing’s? Management is meeting with the FDA to chart a path forward for relacorilant in hypercortisolism (www.drugs.com). Will the company need to conduct another costly Phase 3 trial to address the FDA’s efficacy concerns, or is there a way to resubmit with existing data (perhaps with post-hoc analyses or an interim data cut)? How long might approval now be delayed – and is the potential market still attractive given new competitors and generics? The outcome of FDA discussions (and whether Corcept decides to continue pouring R&D dollars into this indication) is a crucial near-term catalyst.

– What will happen with the ovarian cancer indication? A key binary event in mid-2026 will be the FDA’s decision on relacorilant for platinum-resistant ovarian cancer (PDUFA date July 11, 2026) (www.drugs.com). This is a different use-case (oncology vs. endocrine) and is based on the positive ROSELLA trial data. Approval here could open a new revenue stream and partially validate Corcept’s drug development platform outside Cushing’s. However, questions remain: if approved, how quickly can Corcept commercialize in oncology (a field with entrenched players)? Will oncologists adopt a cortisol modulator added to chemo as a new standard, and what might peak sales look like? Conversely, if the FDA raises concerns or issues another CRL, Corcept’s pipeline narrative would suffer a further blow.

– How steep will Korlym’s decline be? Thus far, Corcept managed to keep Korlym revenues growing through 2025 despite an onslaught of competition – thanks to aggressive marketing, price increases, and launching an authorized generic to capture price-sensitive demand. But with Teva’s generic on the market throughout 2025 and now fully unfettered post-litigation (www.sec.gov), as well as the launch of alternative therapies (Isturisa, Recorlev) (www.sec.gov) (www.sec.gov), 2026 could be the inflection point where Korlym sales flatten or fall. Investors will be watching prescription trends closely. Management has likely provided or will provide 2026 revenue guidance – how conservative is it, and can Corcept mitigate erosion (e.g. by differentiating Korlym’s clinical profile or leveraging its patient support programs)? The extent of Korlym’s decline will heavily influence near-term earnings and cash flow, and therefore the company’s ability to fund development or consider strategic moves.

– Will cost discipline improve? Corcept ramped its operating expenses dramatically in anticipation of growth (SG&A jumped 60%+ in 2025, R&D also grew) (www.sec.gov). If Korlym sales now come under pressure and relacorilant’s approval is delayed, will management adjust spending accordingly? One open question is whether Corcept will right-size its SG&A (for instance, reducing the sales force or marketing spend if fewer new patients start Korlym). Similarly, can R&D be prioritized more efficiently – focusing on the most promising programs and perhaps pausing lower-priority projects – to conserve cash? The company’s significant cash reserves provide a cushion, but continued high cash burn without clear returns could become untenable. How management balances investment vs. austerity in this transitional period will signal their strategic acumen.

– How will the class action and governance issues resolve? While the shareholder lawsuit may take time to play out, any discovery or outcome could shine a light on internal processes. Will Corcept consider governance changes or additional oversight to prevent future miscommunication (e.g., enhancing risk management around regulatory dealings or separating the Chief Executive and Chairman roles)? Thus far there’s no indication of management changes, but investor pressure could mount if the stock remains depressed. It’s also worth asking if Corcept’s high insider ownership (≈21%) (www.sec.gov) aligns management’s interests with shareholders enough, or if fresh independent voices (activist investors, new board members) might be needed to challenge entrenched assumptions.

– Does Corcept become a takeover target? With the stock down sharply from its highs and a still-profitable orphan drug business, could a larger pharma or private equity see value here? Mifepristone for Cushing’s is a niche but cash-generative asset (even if shrinking), and an acquirer might value relacorilant’s potential more highly if they have resources to navigate the FDA process. However, Corcept’s poison pill provisions and insider control could deter unsolicited bids (www.sec.gov). It remains an open question whether management would entertain a strategic partnership or sale, especially if relacorilant in oncology shows promise. Any signs of consolidation interest could buoy the stock, but absent that, Corcept must prove it can execute an effective turnaround solo.

In conclusion, Corcept Therapeutics faces a pivotal period. The company’s past success with Korlym has hit the reality of competition and regulatory hurdles. Investors are rightfully concerned – as evidenced by the class action and stock collapse – but the story isn’t over. Corcept still has financial strength (no debt, ample cash) and a pipeline that, while shaken, is not empty. The next few quarters will provide clarity on whether management can address the FDA’s concerns, stabilize Korlym’s franchise, and deliver new growth from relacorilant or other candidates. Until then, caution is warranted. The stock’s risk profile is high, and much of its valuation hinges on successfully overcoming the challenges outlined. Transparency and execution will be key to restoring market trust. For now, CORT investors are on alert, watching closely how this embattled biotech navigates the storm.

Sources: Authoritative company filings and press releases, including Corcept’s 2025 annual report (Form 10-K) (www.sec.gov) (www.sec.gov), Business Wire FDA update (www.drugs.com), and class action notices (www.globenewswire.com) (intellectia.ai). These and other cited references provide the factual grounding for the analysis above.

For informational purposes only; not investment advice.